The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

September 2020

Volume 16 Number 7

In valvular disease and heart failure a meta-analysis looks at the safety and efficacy of ViV-TAVI; an article examines the challenge of imaging and sizing in TAVI faced with abnormal aortic cusps; in coronary interventions defining complex PCIs from the large e-Ultimaster multicentre registry and a microfocus on intracoronary physiology indices with results from the HYPEREMIC trial on continuous IC adenosine infusion using a dedicated microcatheter; the diagnostic performance of OFR vs QFR; articles on new software to calculate vessel FFR (vFFR) or the optimisation of physiology-guided revascularisation in coronary disease; and a substudy of the DANAMI-3-PRIMULTI trial on FFR-guided PCI in patients with left ventricular hypertrophy.

Highlights from this issue

Long-term outcomes of complex PCI
Long-term outcomes of complex PCI
Mohamed M, Polad J, Hildick-Smith D, Bizeau O, Baisebenov R, Roffi M, Iniguez-Romo A, Chevalier B, von Birgelen C, Roguin A, Aminian A, Angioi M, Mamas M
September 18, 2020
DOI: 10.4244/EIJ-D-20-00361

Interventions for valvular disease and heart failure

Coronary interventions - Mini focus: Physiology indices